Standout Papers

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): re... 2018 2026 2020 2023 435
  1. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials (2018)
    Kenneth B. Gordon, Bruce Strober et al. The Lancet
  2. Trial of Spesolimab for Generalized Pustular Psoriasis (2021)
    H. Bachelez, Siew Eng Choon et al. New England Journal of Medicine

Immediate Impact

60 standout
Sub-graph 1 of 20

Citing Papers

Dendritic cell maturation in cancer
2025 Standout
Atopic dermatitis
2025 Standout
2 intermediate papers

Works of H. Bachelez being referenced

Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
2021
388 Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways
2019
and 2 more

Author Peers

Author Last Decade Papers Cites
H. Bachelez 1160 779 287 40 1.4k
Mary Flack 1277 763 297 22 1.4k
Yoshinori Umezawa 823 531 190 70 1.3k
Darryl Toth 1161 918 222 33 1.7k
Zenas Z N Yiu 1190 850 278 72 1.7k
Marco Galluzzo 987 681 293 81 1.3k
Antonella Di Cesare 1128 711 223 37 1.5k
Satveer K. Mahil 1066 630 221 44 1.4k
Angelo Ruggiero 960 855 256 98 1.5k
A.B. Gottlieb 1102 531 171 33 1.4k
Siew Eng Choon 998 675 307 50 1.4k

All Works

Loading papers...

Rankless by CCL
2026